Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study – Eliem Therapeutics (NASDAQ:ELYM)

 Eliem Therapeutics Inc ELYM announced interim results from its ongoing Phase 1 trial of ETX-155 for important depressive condition…
Business is the only